- Current report filing (8-K)
07 7월 2009 - 10:03PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported):
July 7, 2009
ALLOS
THERAPEUTICS, INC.
(Exact name of registrant
as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
11080
CirclePoint Road, Suite 200
|
|
|
Westminster,
Colorado
|
|
80020
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
Registrants telephone
number, including area code:
(303) 426-6262
Not
applicable
(Former name or former
address, if changed since last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2.
below):
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 8
Other Events
Item
8.01 Other Events.
On July 7, 2009,
Allos Therapeutics, Inc., a Delaware corporation
(the Company), issued a press release
announcing the completion of patient enrollment in the Companys
randomized Phase 2b clinical trial comparing pralatrexate to erlotinib
(Tarceva®) in patients with Stage IIIB/IV non-small cell lung cancer who are,
or have been, cigarette smokers who have failed treatment with at least one
prior platinum-based chemotherapy regimen.
The press release is attached
hereto as Exhibit 99.1 and incorporated herein by reference.
Section 9
Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1
|
|
Press Release, dated
July 7, 2009, entitled Allos
Therapeutics Completes Enrollment in Randomized Phase 2b Trial of
Pralatrexate in Patients with Advanced Non-Small Cell Lung Cancer.
|
2
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: July 7, 2009
|
|
ALLOS THERAPEUTICS, INC.
|
|
|
|
|
|
By:
|
/s/ Marc H. Graboyes
|
|
|
Marc H. Graboyes
|
|
Its:
|
Senior Vice President,
General Counsel
|
3
EXHIBIT
INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated
July 7, 2009, entitled Allos
Therapeutics Completes Enrollment in Randomized Phase 2b Trial of
Pralatrexate in Patients with Advanced Non-Small Cell Lung Cancer.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024